China's domestic retail refined fuel price ceiling is likely to be reduced at 24:00 on Nov. 12, the first cut since late August, after international crude fell sharply during the current pricing cycle amid the US midterm outcome, easing Middle East tensions and reports of US‑Iran talks. As of the ninth working day through Nov. 10 the reference crude oil change rate stood at -9.28%, implying an expected reduction of 410 yuan/ton for gasoline and diesel — roughly 0.3 yuan/liter for 92 RON gasoline

2026-11-11

China's domestic retail refined fuel price ceiling is likely to be reduced at 24:00 on Nov. 12, the first cut since late August, after international crude fell sharply during the current pricing cycle amid the US midterm outcome, easing Middle East tensions and reports of US‑Iran talks. As of the ninth working day through Nov. 10 the reference crude oil change rate stood at -9.28%, implying an expected reduction of 410 yuan/ton for gasoline and diesel — roughly 0.3 yuan/liter for 92 RON gasoline and 0 diesel. Filling 50 liters of 92 RON would save about 15 yuan. With one business day remaining before the pricing window, the cut is a high‑probability event; lower retail fuel costs would reduce passenger and logistics fuel expenses during the two‑week pricing period from 24:00 Nov. 12 to 24:00 Nov. 26.

其他消息
2026-11-10

On Nov. 10 in Beijing, Liu Haixing, minister of the International Liaison Department of the Communist Party of China, held separate meetings with Moussa, secretary‑general of the Congolese Labour Party, and former Italian prime minister Massimo D'Alema to discuss implementing leaders' consensus, strengthening exchanges and cooperation, and advancing China‑Africa and China‑Europe relations.

2026-11-10

Betta Pharmaceuticals said its pan‑RAS inhibitor BPI‑572270 capsule completed first‑participant dosing in an Australia Phase I/II study today. Preclinical data show strong inhibition in tumor cells and xenograft models with diverse RAS mutations (KRAS, NRAS, HRAS, including G12X, G13X, Q61X) across pancreatic, non‑small‑cell lung and colorectal cancers, and report favorable pharmacokinetics and safety.